Chinese Journal of Tissue Engineering Research ›› 2011, Vol. 15 ›› Issue (36): 6709-6713.doi: 10.3969/j.issn.1673-8225.2011.36.014

Previous Articles     Next Articles

Differentiation of human amnion derived-mesenchymal stem cells into hepatocytes in rat injured liver 

Gong Li-ming1, Fang Ning1, Chen Dai-xiong1, Wan Wei-hong1, Zhang Tao1, Liu Zu-lin1, Yu Li-mei1, Zhao Chun-hua2   

  1. 1Key Laboratory of Cell Engineering of Guizhou Province, Affiliated Hospital of Zunyi Medical College, Zunyi  563003, Guizhou Province, China
    2Tissue Engineering Center, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences, Beijing  100005, China
  • Received:2011-03-01 Revised:2011-04-12 Online:2011-09-03 Published:2011-09-03
  • Contact: Chen Dai-xiong, Master, Professor, Doctoral supervisor, Key Laboratory of Cell Engineering of Guizhou Province, Affiliated Hospital of Zunyi Medical College, Zunyi 563003, Guizhou Province, China cellgene@163.com
  • About author:Gong Li-ming★, Master, Key Laboratory of Cell Engineering of Guizhou Province, Affiliated Hospital of Zunyi Medical College, Zunyi 563003, Guizhou Province, China aschac@163.com
  • Supported by:

    the National Science and Technology Issues of Significant New Drug Innovation and Manufacture, No. 2009ZX09503-025*; the Science and Technology Program of Guizhou Province, No. 2051, SZ 3017*

PDF

289

Abstract:

BACKGROUND: Human amnion derived-mesenchymal stem cells (hAD-MSCs) can differentiate into hepatocyte-like cells in certain conditions in vitro. It needs to further investigate whether they can differentiate into hepatocytes in damaged liver.
OBJECTIVE: To study the survival and differentiation of hAD-MSCs in vivo in rat injured liver.
METHODS: hAD-MSCs were isolated from human amnion treated with trypsin and collagenase. Forty healthy and clean grade female SD rats underwent intraperitoneal injection of D-galactosamine diluted in normal saline at the dose of 400 mg/kg body weight, to establish the model of liver injury, and then divided into hAD-MSCs group and control group stochastically. Twenty-four hours after modeling, 50 μL cell suspension (approximately 1×106 cells suspended in L-DMEM) of hAD-MSCs were injected slowly into the left, middle and right hepatic lobe respectively with micro-syringe, while equivalent volume of L-DMEM injected into the control group.
RESULTS AND CONCLUSION: ①Freshly isolated hAD-MSCs expressed CD29, CD44 and CD166; immunofluorescence staining showed that vimentin was positive in hAD-MSCs, while cytokeratin 19 was negative. ②There was no significant difference after transplanting hAD-MSCs into injured liver between the hAD-MSCs group and the control group, remaining acute hepatic necrosis. ③hAD-MSCs implanted into injured liver were located in hepatic lobules at day 7 after transplantation, which expressed CK19; and the cells expressed CK18 at day 14, and also human Alb at day 21. hAD-MSCs xenografted to rat injured liver can survive and differentiate into hepatocytes, suggesting that hAD-MSCs transplantation may have potential applications for treating clinical liver injury diseases.

CLC Number: